LL-37
Fights infections and boosts immune defense
- Chronic Infections (bacterial/viral/fungal)
- Immune System Modulation
No human clinical trials have systematically evaluated the safety of exogenous LL-37 administration May exacerbate inflammatory skin conditions such as rosacea through CXCL10/T-cell pathway activation Dose-dependent cytotoxicity observed in cell studies - safety margins in humans are undefined
Mechanism of Action
LL-37 is a human cathelicidin antimicrobial peptide that disrupts microbial membranes through direct electrostatic interactions with negatively charged pathogen surfaces, leading to membrane permeabilization and cell death. Beyond direct antimicrobial activity, LL-37 modulates immune responses by binding to pattern recognition receptors and activating intracellular signaling pathways including Jak1/STAT1, which regulates chemokine production and inflammatory responses. Key Pathways: Direct membrane disruption of bacterial/fungal cell walls, Jak1/STAT1 signaling pathway activation, Reactive oxygen species (ROS)-mediated mucus secretion regulation, Chemokine induction (CXCL10) for immune cell recruitment The dual antimicrobial and immunomodulatory properties of LL-37 may help clear chronic infections while simultaneously regulating inflammatory responses. In wound healing contexts, LL-37 promotes cell migration and proliferation while preventing infection, and in gut immunity, it regulates mucus secretion critical for bacterial clearance.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full LL-37 protocols — frequency, timing, cycle length, reconstitution & research
- Cytotoxicity at high concentrations
- Pro-inflammatory responses
- Immunomodulatory effects
- Limited proteolytic stability